CONMED Co. (NYSE:CNMD) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. increased its stake in CONMED Co. (NYSE:CNMD) by 0.4% in the fourth quarter, Holdings Channel reports. The firm owned 382,950 shares of the company’s stock after purchasing an additional 1,537 shares during the period. Charles Schwab Investment Management Inc.’s holdings in CONMED were worth $26,209,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of CNMD. Fisher Asset Management LLC boosted its stake in CONMED by 41.4% in the 4th quarter. Fisher Asset Management LLC now owns 417,430 shares of the company’s stock worth $28,569,000 after purchasing an additional 122,140 shares in the last quarter. Champlain Investment Partners LLC boosted its stake in CONMED by 6.4% in the 3rd quarter. Champlain Investment Partners LLC now owns 1,367,650 shares of the company’s stock worth $98,361,000 after purchasing an additional 81,970 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its stake in CONMED by 44.5% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 223,142 shares of the company’s stock worth $15,029,000 after purchasing an additional 68,696 shares in the last quarter. Natixis Advisors LLC boosted its stake in CONMED by 36.6% in the 3rd quarter. Natixis Advisors LLC now owns 110,909 shares of the company’s stock worth $7,977,000 after purchasing an additional 29,720 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its stake in CONMED by 4.2% in the 3rd quarter. Principal Financial Group Inc. now owns 620,715 shares of the company’s stock worth $44,631,000 after purchasing an additional 25,047 shares in the last quarter.

CONMED Stock Performance

CNMD opened at $61.46 on Tuesday. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.30 and a quick ratio of 1.06. The firm has a fifty day moving average price of $65.32 and a 200 day moving average price of $68.81. CONMED Co. has a 1 year low of $55.22 and a 1 year high of $81.22. The stock has a market cap of $1.90 billion, a P/E ratio of 14.50, a P/E/G ratio of 1.83 and a beta of 1.53.

CONMED (NYSE:CNMD) last posted its earnings results on Wednesday, February 5th. The company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.20 by $0.14. CONMED had a net margin of 10.13% and a return on equity of 14.31%. Equities research analysts anticipate that CONMED Co. will post 4.35 earnings per share for the current year.

CONMED Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, April 4th. Investors of record on Friday, March 14th will be paid a $0.20 dividend. This represents a $0.80 annualized dividend and a dividend yield of 1.30%. The ex-dividend date is Friday, March 14th. CONMED’s dividend payout ratio is currently 18.87%.

Wall Street Analysts Forecast Growth

Several analysts have commented on CNMD shares. Wells Fargo & Company decreased their price objective on shares of CONMED from $74.00 to $70.00 and set an “equal weight” rating for the company in a research note on Thursday, February 6th. Stifel Nicolaus lifted their price objective on shares of CONMED from $72.00 to $75.00 and gave the company a “buy” rating in a research note on Thursday, February 6th. Needham & Company LLC decreased their price objective on shares of CONMED from $97.00 to $91.00 and set a “buy” rating for the company in a research note on Thursday, February 6th. Finally, JPMorgan Chase & Co. cut shares of CONMED from an “overweight” rating to a “neutral” rating and decreased their price objective for the company from $85.00 to $70.00 in a research note on Thursday, February 6th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $77.20.

CONMED Profile

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.